Insmed (NASDAQ:INSM) 주식

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Exclusives

Trading Ideas

DKNG

INSM

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: M&amp;T 뱅크, 드래프트킹스, TJX 컴퍼니즈, 인스메드 및 트레인 테크

ISRG

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

Equities

Large Cap

News

Movers

BIDU

NYCB

RIVN

SIRI

Sony Group Corporation American Depositary Shares

SONY

EMPH

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 리비안 오토모티브(NASDAQ:RIVN)의 주식은 최근 CPI 데이터에 지난주 21.37% 상승했다. 또한 미국 에너지부(Department of Energy)는 폐쇄되었거나 위험에 처한 11개 자동차 시설을 전기 자동차 제조 공장 및 공급망 허브로 전환하기 위해 17억 달러 투자를 공개했다. 

리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)

Insmed Inc

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $105 to $108.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Insmed, Raises Price Target to $108

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $97 to $96.

Stifel Maintains Buy on Insmed, Lowers Price Target to $96

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Insmedto Overweight

General

Insmed shares are trading lower after the company reported Q4 financial results and missed its EPS estimate.

As of December 31, 2024, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.4 billion.
The Company plans to continue to invest in the following key activities in 2025:
<ul>
<li>Commercialization and expansion of ARIKAYCE globally.</li>
<li>Commercial launch of brensocatib in the U.S., if approved, with advancement of regulatory submissions in the EU, UK, and Japan.</li>
<li>Advancement of clinical trial programs for brensocatib, including the ongoing Phase 2b BiRCh study in patients with CRSsNP and the Phase 2b CEDAR study in patients with HS.</li>
<li>Advancement of the clinical trial program for ARIKAYCE, which is intended to satisfy the post-marketing requirement for full approval of its current indication and potentially support label expansion to include all patients with a MAC lung infection.</li>
<li>Advancement of the clinical development programs for TPIP, including the Phase 2b study in patients with PAH and the initiation of a Phase 3 study in patients with PH-ILD.</li>
<li>Advancement of the clinical trial program for INS1201 in DMD.</li>
<li>Continued development of its pre-clinical research programs</li>
</ul>

Biotech

Earnings

Guidance

Health Care

Insmed Continues To Anticipate Full-year 2025 Global Arikayce Revenues In The Range Of $405M-$425M, Representing Between 11% And 17% Year-over-year Growth Compared To 2024

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.17) by 12.82 percent. This is a 3.13 percent decrease over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $104.44 million which beat the analyst consensus estimate of $101.79 million by 2.60 percent. This is a 24.79 percent increase over sales of $83.69 million the same period last year.

Insmed Q4 2024 GAAP EPS $(1.32) Misses $(1.17) Estimate, Sales $104.44M Beat $101.79M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $85 to $107.

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $107

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 4.85% on an annualized basis producing an average annual return of 16.1%. Currently, Insmed has a market capitalization of $14.02 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $440.03 today based on a price of $78.37 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739551507_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 3.63% since its last report. The company recently reported that it has 14.54 million shares sold short, which is 8.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739545211_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Insmed's Recent Short Interest

Ratings for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Insmed, revealing an average target of $92.6, a high estimate of $101.00, and a low estimate of $83.00. Surpassing the previous average price target of $85.00, the current average has increased by 8.94%.
<img src="https://www.benzinga.com/files/images/story/2025/1739300419_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Insmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insmed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Insmed's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h2>Unveiling the Story Behind Insmed</h2>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
<h3>Unraveling the Financial Story of Insmed</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Insmed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 18.15%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -236.04%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -84.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.42%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Insmed's debt-to-equity ratio is below the industry average. With a ratio of 2.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Stifel analyst Stephen Willey maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $88 to $97.

Stifel Maintains Buy on Insmed, Raises Price Target to $97

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $83 to $92.

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $92

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $95 to $101.

Guggenheim Maintains Buy on Insmed, Raises Price Target to $101

—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved—
BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. In its Day 60 communication to Insmed, the&nbsp;FDA&nbsp;granted Priority Review to the NDA and set a target action date of&nbsp;August 12, 2025, under the Prescription Drug User Fee Act (PDUFA). At present, the FDA has not indicated whether an advisory committee will be convened to discuss the application.&nbsp;Brensocatib has the potential to become the first and only approved treatment for bronchiectasis and the first in a new class of medicines called dipeptidyl peptidase 1 (DPP1) inhibitors for the treatment of neutrophil-mediated diseases.

Insmed Announces FDA Priority Review For Brensocatib, Aiming To Be First Treatment For Bronchiectasis And First DPP1 Inhibitor; Target Action Date Is August 12, 2025

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 8.73% on an annualized basis producing an average annual return of 21.22%. Currently, Insmed has a market capitalization of $14.42 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 5 years ago, it would be worth $2,490.11 today based on a price of $80.58 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738788309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 18.59% since its last report. The company recently reported that it has 15.44 million shares sold short, which is 8.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736792122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.01%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Insmed?

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In 2024 — Where Do Tesla, Nvidia, GameStop, Trump Media Stocks Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending Jan. 10:
M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>): The regional bank saw strong interest from Benzinga readers during the week, which comes ahead of the company's fourth-quarter financial results. Analysts expect the company to report earnings per share of $3.73, up from $2.81 in last year's fourth quarter and to report revenue of $2.34 billion, up from $2.30 billion in last year's fourth quarter. The company has beaten analyst estimates for revenue and earnings per share in seven of the last 10 quarters for each. Analysts <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">have spoken positively </a>of regional banks recently with Truist <a href="https://www.benzinga.com/general/market-summary/25/01/42871340/regional-banks-can-thrive-despite-big-bank-dominance-truist-securities-highlights-three-key-paths-for-thriving-regional-banks">initiating the stock</a> with a Buy rating and $233 price target. Barclays maintained an Equal-weight rating and raised the price target from $228 to $235. Truist said regional banks have differentiated growth, disciplined capital allocation and can navigate to the evolving landscape.
The<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"> Benzinga Pro chart</a> below shows the five-day trading range of MTB with shares down on the week. The stock remains up over 35% over the last year.
<figure class="wp-block-image size-full"><a href=" https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145206/Screenshot-290.png" alt="" class="wp-image-728860" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145206/Screenshot-290.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145206/Screenshot-290-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145206/Screenshot-290-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>): The sports betting and online gaming company saw increased interest from readers during the week, which comes as<a href="https://www.benzinga.com/general/sports/25/01/42829221/how-to-watch-nfl-playoffs-super-bowl-lix-betting-odds-will-history-be-made-by-chiefs-or-lions"> the NFL Playoffs </a>are set to kick off on Jan. 11. The NFL remains one of the most bet on sports worldwide and a major source of revenue for DraftKings. Peer company Flutter recently lowered guidance for the full fiscal year due to <a href="https://www.benzinga.com/general/sports/25/01/42884959/detroit-lions-take-a-bite-out-of-sportsbooks-analyst-advises-patience-after-flutter-cuts-guidance">unfavorable NFL outcomes</a>, something DraftKings had already done and commented on. DraftKings could be getting more attention as the company got ahead of the guidance and NFL warnings earlier than peers and shares could now look attractive. DraftKings shares were up around 10% over the last five days and the stock is up around 18% over the last year.
<figure class="wp-block-image size-full"><a href=" https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145223/Screenshot-291.png" alt="" class="wp-image-728861" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145223/Screenshot-291.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145223/Screenshot-291-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145223/Screenshot-291-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
TJX Companies (NYE:TJX): The discount retailer, which owns the T.J. Maxx, Marshalls and Home Goods brands, saw increased interest during the week. The retailer was recently <a href="https://www.benzinga.com/trading-ideas/24/12/42694713/super-saturday-foot-traffic-surges-sales-hit-157-million-potential-winners-emerge">highlighted by Benzinga</a> as a potential winner from Super Saturday, the shopping holiday that is the last Saturday before Christmas. A Placer.ai report said foot traffic at retailers on Super Saturday was up an average of 58% compared to daily averages in 2024. T.J. Maxx foot traffic was up 4.6% on a year-over-year basis for Super Saturday according to the report. In recent weeks, the retailer has received several <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">price target increases</a> from analysts, including Wells Fargo, UBS and Bernstein at $120, $151 and $145 respectively. The stock is up around 28% over the last year.
<figure class="wp-block-image size-full"><a href=" https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145239/Screenshot-292.png" alt="" class="wp-image-728862" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145239/Screenshot-292.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145239/Screenshot-292-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145239/Screenshot-292-768x386.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>): The biopharmaceutical company saw increased interest after <a href="https://investor.insmed.com/2025-01-10-Insmed-Provides-Business-Update-at-43rd-Annual-J-P-Morgan-Healthcare-Conference">sharing </a>a business update at the JPMorgan Healthcare Conference, including 2025 guidance. The company said ARIKAYCE, its first commercial product, is expected to have full year revenue of $363.7 million globally, including $254.8 million in the United States. Guidance for ARIKAYCE for 2025 was set at a range of $405 million to $425 million. Insmed also shared an update on its other pipeline drugs with an NDA submitted in December 2024 for Brensocatib, expected to launch in the third quarter of 2025. The company also announced several other pipeline updates, which may have investors taking a new look at the stock. Insmed previously appeared on the Stock Whisper Index<a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42"> back in November</a> after reporting third-quarter financial results and receiving several analyst updates. Shares fell during the week, but are up over 130% over the last year.
<figure class="wp-block-image size-full"><a href=" https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145253/Screenshot-294.png" alt="" class="wp-image-728864" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145253/Screenshot-294.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145253/Screenshot-294-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145253/Screenshot-294-768x388.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>): The commercial and residential HVAC company appears on the list after seeing a boost in interest from readers. The company announced it will report fourth-quarter financial results on Jan. 30. Analysts expect the company to report earnings per share of $2.52, up from $2.17 in last year's fourth quarter and to report revenue of $4.77 billion, up from $4.43 billion in last year's fourth quarter. The company has beaten earnings estimates in more than 10 straight quarters and beaten revenue estimates in nine of the last 10 quarters, including three straight quarters. Trane Technologies recently <a href="https://investors.tranetechnologies.com/news-and-events/news-releases/news-release-details/2025/Trane-Technologies-Completes-Acquisition-of-BrainBox-AI/default.aspx">announced </a>the closing of its acquisition of BrainBox AI, which it announced in December 2024. Brain Box AI is a pioneer in autonomous HVAC controls and generative AI building technology, according to the announcement. While HVAC might not be a sector that jumps out as an AI use case, the company's acquisition could be the reason why readers are paying more attention to Trane Technologies. Analysts were mixed <a href="https://www.benzinga.com/quote/TT/analyst-ratings">in recent weeks </a>with Wells Fargo lowering the price target, RBC raising the price target and Barclays maintaining a Buy rating and $500 price target.
<figure class="wp-block-image size-full"><a href=" https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145308/Screenshot-295.png" alt="" class="wp-image-728865" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145308/Screenshot-295.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145308/Screenshot-295-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10145308/Screenshot-295-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">December 13</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts" target="_blank" rel="noreferrer noopener">December 20</a></li>
<li><a href="https://www.benzinga.com/media/24/12/42709387/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">December 27</a></li>
<li><a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">January 3 </a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42638753/quantum-computing-the-new-ai-a-look-at-the-rapidly-expanding-market-and-top-stocks-for-2025" target="_blank" rel="noreferrer noopener">Quantum Computing: The New AI? A Look at the Rapidly Expanding Market and Top Stocks For 2025</a></li>
</ul>

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Press Releases

Insmed To Present at December 2024 Investor Conferences

Offerings

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed To Present at March 2025 Investor Conferences

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Comments

Insmed

뉴스

파트너 / 기고자

벤징가 글로벌